Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice

European Journal of Pharmacology

Volumn 809, Issue , 2017, Pages 163-171

  Tahara, Atsuo ^a   Takasu, Toshiyuki ^a   Yokono, Masanori ^a   Imamura, Masakazu ^a   Kurosaki, Eiji ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Diabetes; Diabetic complications; Hyperglycemia; Ipragliflozin; SGLT2 inhibitor

Indexed keywords

4 HYDROXYNONENAL; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CANAGLIFLOZIN; CHOLESTEROL; CREATININE; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCOSE; HEMOGLOBIN A1C; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; IPRAGLIFLOZIN; KIDNEY INJURY MOLECULE 1; LUSEOGLIFLOZIN; MONOCYTE CHEMOTACTIC PROTEIN 1; N ACETYL BETA GLUCOSAMINIDASE; NEPHRIN; PODOCALYXIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TOFOGLIFLOZIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG POTENCY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FATTY LIVER; GLYCEMIC CONTROL; INFLAMMATION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; COMPLICATION; DOSE RESPONSE; METABOLISM;

ANIMALS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85019855786     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2017.05.019     Document Type: Article

References (35)

1. Akash, M.S., Rehman, K., Chen, S., Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J. Cell Biochem. 114 (2013), 525–531.
2. Angulo, P., Nonalcoholic fatty liver disease. N. Engl. J. Med. 346 (2002), 1221–1231.
3. Atkinson, M.A., Eisenbarth, G.S., Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358 (2001), 221–229.
4. Cade, W.T., Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys. Ther. 88 (2008), 1322–1335.
5. Ding, H., Triggle, C.R., Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vasc. Health Risk Manag. 1 (2005), 55–71.
6. Fruci, B., Giuliano, S., Mazza, A., Malaguarnera, R., Belfiore, A., Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int. J. Mol. Sci. 14 (2013), 22933–22966.
7. Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D.E., Bakker, R.A., Mark, M., Klein, T., Eickelmann, P., Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes. Metab. 14 (2012), 83–90.
8. Hermansen, K., Mortensen, L.S., Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf. 30 (2007), 1127–1142.
9. Inoue, K., Maeda, N., Fujishima, Y., Fukuda, S., Nagao, H., Yamaoka, M., Hirata, A., Nishizawa, H., Funahashi, T., Shimomura, I., Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study. Diabetol. Metab. Syndr., 6, 2014, 95.
10. Kahn, S.E., Hull, R.L., Utzschneider, K.M., Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444 (2006), 840–846.
11. Koga, M., Otsuki, M., Kubo, M., Hashimoto, J., Kasayama, S., Relationship between circulating vascular cell adhesion molecule-1 and microvascular complications in type 2 diabetes mellitus. Diabet. Med. 15 (1998), 661–667.
12. Kojima, N., Williams, J.M., Takahashi, T., Miyata, N., Roman, R.J., Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J. Pharmacol. Exp. Ther. 34 (2013), 464–472.
13. Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., Pfister, M., Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin. Pharmacol. 85 (2009), 513–519.
14. Kurosaki, E., Ogasawara, H., Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol. Ther. 139 (2013), 51–59.
15. Laakso, M., Hyperglycemia as a risk factor for cardiovascular disease in type 2 diabetes. Prim. Care 26 (1999), 829–839.
16. Liang, Y., Arakawa, K., Ueta, K., Matsushita, Y., Kuriyama, C., Martin, T., Du, F., Liu, Y., Xu, J., Conway, B., Conway, J., Polidori, D., Ways, K., Demarest, K., Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One, 7, 2012, e30555.
17. Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A.J., Natale, S., Forlani, G., Melchionda, N., Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001), 1844–1850.
18. Meigs, J.B., Hu, F.B., Rifai, N., Manson, J.E., Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 291 (2004), 1978–1986.
19. Nalysnyk, L., Hernandez-Medina, M., Krishnarajah, G., Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes. Metab. 12 (2010), 288–298.
20. Narasimhan, S., Gokulakrishnan, K., Sampathkumar, R., Farooq, S., Ravikumar, R., Mohan, V., Balasubramanyam, M., Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clin. Biochem. 43 (2010), 815–821.
21. Nauck, M.A., Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des. Devel. Ther. 8 (2014), 1335–1380.
22. Navarro-Gonzalez, J.F., Mora-Fernandez, C., The role of inflammatory cytokines in diabetic nephropathy. J. Am. Soc. Nephrol. 19 (2008), 433–442.
23. Pan, H.Z., Zhang, L., Guo, M.Y., Sui, H., Li, H., Wu, W.H., Qu, N.Q., Liang, M.H., Chang, D., The oxidative stress status in diabetes mellitus and diabetic nephropathy. Acta Diabetol. 47 (2010), 71–76.
24. Shams, M.E., Al-Gayyar, M.M., Barakat, E.A., Type 2 Diabetes Mellitus-Induced Hyperglycemia in Patients with NAFLD and Normal LFTs: relationship to Lipid Profile, Oxidative Stress and Pro-Inflammatory Cytokines. Sci. Pharm. 79 (2011), 623–634.
25. Sharma, V., Sharma, P.L., Role of different molecular pathways in the development of diabetes-induced nephropathy. J. Diabetes Metab., S9, 2013, 004.
26. Suzuki, M., Honda, K., Fukazawa, M., Ozawa, K., Hagita, H., Kawai, T., Takeda, M., Yata, T., Kawai, M., Fukuzawa, T., Kobayashi, T., Sato, T., Kawabe, Y., Ikeda, S., Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J. Pharmacol. Exp. Ther. 341 (2012), 692–701.
27. Tahara, A., Matsuyama-Yokono, A., Shibasaki, M., Effects of antidiabetic drugs in high-fat diet and streptozotocin–nicotinamide-induced type 2 diabetic mice. Eur. J. Pharmacol. 655 (2011), 108–116.
28. Tahara, A., Takasu, T., Yokono, M., Imamura, M., Kurosaki, E., Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. J. Pharmacol. Sci. 130 (2016), 159–169.
29. Tahara, A., Takasu, T., Yokono, M., Imamura, M., Kurosaki, E., Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: part 2. Antidiabetic effects in type 2 diabetic mice. J. Pharmacol. Sci. 131 (2016), 198–208.
30. Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Qun, L., Tomiyama, H., Kobayashi, Y., Noda, A., Sasamata, M., Shibasaki, M., Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiede.'S. Arch. Pharmacol. 385 (2012), 423–436.
31. Uehara, Y., Kawabata, Y., Shirahase, H., Wada, K., Hashizume, Y., Morishita, S., Numabe, A., Iwai, J., Oxygen radical scavengers and renal protection by indapamide diuretic in salt-induced hypertension of Dahl strain rats. Hypertens. Res. 15 (1993), 17–26.
32. UK Prospective Diabetes Study (UKPDS), VIII. study design, progress and performance. Diabetologia 34 (1991), 877–890.
33. Yamazaki, M., Hasegawa, G., Majima, S., Mitsuhashi, K., Fukuda, T., Iwase, H., Kadono, M., Asano, M., Senmaru, T., Tanaka, M., Fukui, M., Nakamura, N., Effect of repaglinide versus glimepiride on daily blood glucose variability and changes in blood inflammatory and oxidative stress markers. Diabetol. Metab. Syndr., 6, 2014, 54.
34. Yokono, M., Takasu, T., Hayashizaki, Y., Mitsuoka, K., Kihara, R., Muramatsu, Y., Miyoshi, S., Tahara, A., Kurosaki, E., Li, Q., Tomiyama, H., Sasamata, M., Shibasaki, M., Uchiyama, Y., SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur. J. Pharmacol. 727 (2014), 66–74.
35. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O.E., Woerle, H.J., Broedl, U.C., Inzucchi, S.E., EMPA-REG OUTCOME Investigators, Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N. Engl. J. Med. 50 (2015), 1844–1850.